What is wet macular degeneration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Wet Macular Degeneration: Characteristics and Management

Wet macular degeneration is a form of age-related macular degeneration characterized by the development of abnormal blood vessels in the choroid layer underneath the retina, leading to blurred vision and loss of central vision.

Definition and Pathophysiology

Wet age-related macular degeneration (AMD), also known as neovascular AMD, is a progressive deterioration of the retina that involves:

  • Development of abnormal blood vessels from the choroidal circulation that penetrate through Bruch's membrane 1
  • These new vessels are fragile and can leak fluid or blood into the subretinal space 2
  • Results in distortion of vision and rapid loss of central vision compared to the dry form 1, 3
  • Represents approximately 10-15% of all AMD cases but accounts for about 90% of severe vision loss due to AMD 4, 5

Epidemiology and Risk Factors

  • Prevalence increases significantly with age:
    • 2.8% in adults aged 40-59 years
    • 13.4% in adults 60 years or older 1
  • Overall prevalence of AMD is 6.5% in adults 40 years or older 1
  • Leading cause of blindness in adults over 65 years 1, 4

Key risk factors include:

  • Advancing age (strongest risk factor) 2
  • Smoking (significantly increases risk and progression) 2
  • Family history of AMD 1, 2
  • Presence of drusen (especially large or soft drusen) 1, 2
  • Obesity 2
  • Diet low in green leafy vegetables 2
  • Elevated cholesterol levels 2
  • Cardiovascular disease 2

Clinical Presentation

Patients with wet AMD typically present with:

  • Sudden or rapid deterioration of central vision
  • Visual distortion (metamorphopsia)
  • Central scotoma (blind spot)
  • Difficulty recognizing faces
  • Problems reading or performing detailed tasks
  • Preserved peripheral vision

Diagnosis

Diagnosis of wet AMD involves:

  1. Comprehensive eye examination with dilated fundus evaluation
  2. Amsler grid testing to detect metamorphopsia (distortion of straight lines) 2
  3. Optical Coherence Tomography (OCT) to visualize retinal layers and detect fluid
  4. Fluorescein Angiography to classify the type of choroidal neovascularization (classic vs. occult) and guide treatment decisions 2

Treatment Options

The mainstay of treatment for wet AMD is:

Anti-VEGF Therapy

  • First-line treatment for neovascular AMD 2
  • Intravitreal injections of VEGF inhibitors:
    • Ranibizumab (Lucentis) 6
    • Aflibercept (Eylea) 7
    • Bevacizumab (Avastin, off-label) 4
  • These medications bind and inhibit VEGF, preventing further growth of abnormal blood vessels 7, 6
  • Treatment regimens typically require regular injections, often monthly initially 4

Other Treatment Options

  • Photodynamic therapy (PDT): Combines verteporfin (a photosensitizing agent) with low-level laser light 1
  • Combination therapy: Some studies have explored combining anti-VEGF with PDT 1
  • Antioxidant vitamins and minerals: While primarily used for dry AMD, may have some benefit in preventing progression 1

Prognosis and Monitoring

  • Early detection and prompt treatment are critical for preserving vision 2
  • Anti-VEGF therapy can improve vision in many patients if started early 8
  • Regular monitoring is essential as treatment response varies between patients 9
  • Up to 25% of patients may not fully respond to anti-VEGF therapy (non-responders) 9
  • The contralateral eye in patients with unilateral wet AMD has a high risk of developing the disease and should be monitored closely 2

Prevention Strategies

  • Smoking cessation 2
  • Maintaining a healthy body mass index 2
  • Diet rich in green leafy vegetables and omega-3 fatty acids
  • Regular eye examinations, especially for those with risk factors
  • Use of AREDS2 formula supplements in appropriate patients (vitamins C, E, zinc, copper, lutein, and zeaxanthin) 2
  • Protection from excessive sunlight exposure 2

Wet AMD represents a serious threat to vision, but with early detection and modern treatments, visual outcomes have significantly improved compared to previous decades.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Causes and Management of Visual Spots

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Age-related macular degeneration.

The journal of the British Menopause Society, 2006

Research

Neovascular Age-Related Macular Degeneration.

Developments in ophthalmology, 2016

Research

Different Therapeutic Approaches for Dry and Wet AMD.

International journal of molecular sciences, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.